- Aglaris Cell develops a fully automated bioreactor for stem cell cultures
- The Spanish company was founded in 2012 and currently has offices in Madrid Science Park and London
- It is the eighth investment of the CRB Bio II Fund
CRB Bio II, a fund managed by CRB Inverbío SGECR, has committed 2 million euros to Aglaris Ltd., a company specializing in bioengineering applied to personalized medicine.
Thanks to this capital injection, the alpha prototype of its bioreactor will be financed, a fully functional automatic cell culture equipment internally validated by Aglaris Cell and by the Cell Therapy Catapult in London.
The bioreactor is designed to perform automated stem cell cultures using proprietary and patented technology that allows faster and more controlled production of these cells. Automation also ensures that the process is free from contamination as it does not require human intervention.
Aglaris Facer 1.0, the name of the bioreactor, will systematize and provide ideal conditions for the cultivation and mass production of stem cells, according to specific demand and without the use of compounds that increase the toxicity of the culture medium.
Stem cells are cells with the potential to develop into different types of cells in the body, and they function as a repair system for numerous diseases such as diabetes, Parkinson’s disease, burns, spinal cord injury, and more specifically, heart diseases. As Miquel Costa, one of the three founding partners of Aglaris Cell, states, ‘There is a wide potential market whose growth is limited by the capacity to produce stem cells.’
About Aglaris Cell:
Aglaris Cell S.L. was established as a company in 2012 by its promoters Miquel Costa, David Horna and Manuel Angel González, and has a center in Madrid Science Park and another in the United Kingdom, where it develops both its cell culture biomaterials and bioreactor engineering. In 2014, it created its subsidiary Aglaris Ltd. in London, which has become the parent company since 2015. www.aglariscell.es
About CRB Inverbío:
Cross Road Biotech Inversiones Biotecnológicas (CRB Inverbío SGEIC SA) is an independent venture capital management company that invests in innovative technology-based companies in the early stages in the field of life sciences. The target investments propose innovative solutions to medical needs in a cost-effective manner and are aimed at global markets with large volumes and/or high growth rates.
CRB Inverbío manages two funds totaling over €50M and has a portfolio of 14 investee companies. www.crbinverbio.com
